DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Coya Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

51 Comunicados de prensa

Ver todos los comunicados de prensa
09/04/2026
Industria
Biotecnología
Higiene alimentaria
Salud
Sanidad
Farmacéutica
Ciencia
Psiquiatría
Medicina - Varios
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
02/04/2026
Mercado laboral
Sanidad
Ciencia
Farmacéutica
Medicina - Varios
Biotecnología
Higiene alimentaria
Salud
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
18/03/2026
Análisis de Mercados
Industria
Salud
Biotecnología
Sanidad
Ciencia
Farmacéutica
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
16/03/2026
Psiquiatría
Higiene alimentaria
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Mercado de valores
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
10/02/2026
Web y redes sociales
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
30/01/2026
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Finanzas
Coya Therapeutics Announces $11.1 Million Private Placement
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
20/01/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
08/01/2026
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Análisis de Mercados
Industria
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
05/01/2026
Industria
Psiquiatría
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0
23/12/2025
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Industria
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Fuente
Coya Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0